

- Meerkat Study -

IRB Approved at the
Study Level
March 07, 2023



Uveitic Macular Edema

A Phase III, Multicenter, Randomized, Double-Masked, Sham- Controlled Study To Investigate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of RO7200220 Administered Intravitreally In Patients With Uveitic Macular Edema (Meerkat)

Principal Investigator:
Dr. Ana Suelves Cogollos

INCLUSION CRITERIA:

- Age \geq 18 years with a clinical diagnosis of active, inactive, acute, or chronic non-infectious uveitis (NIU)
- Diagnosis of macular edema (CST \geq 325) associated with NIU
- ETDRS BCVA letter score between 19-73 in study eye at screening visit

EXCLUSION CRITERIA:

- History of vitrectomy
- History of focal or macular laser
- Intraocular/peri-ocular malignancy
- Any macular neovascularization

Ohio State Department of Ophthalmology & Visual Science • 614-293-5287 • Research@osumc.edu

This research is not being conducted by the Columbus Chalmers P. Wiley Ambulatory Care Center. The research has not been reviewed by the Institutional Review Board of the Chalmers P. Wiley VA. The VA is not responsible for any costs incurred by participating in the research study.